Rezolute, Inc. (RZLT)
| Market Cap | 225.19M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -71.13M |
| Shares Out | 60.54M |
| EPS (ttm) | -1.17 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 587,037 |
| Open | 3.610 |
| Previous Close | 3.610 |
| Day's Range | 3.575 - 3.865 |
| 52-Week Range | 2.215 - 6.190 |
| Beta | 1.02 |
| Analysts | Strong Buy |
| Price Target | 12.33 (+231.45%) |
| Earnings Date | May 19, 2025 |
About RZLT
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. The company’s lead product candidate is ersodetug, a human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 2 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known a... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for RZLT stock is "Strong Buy." The 12-month stock price forecast is $12.33, which is an increase of 231.45% from the latest price.
News
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
Registrational study in patients with tumor hyperinsulinism (HI) expected to commence mid-year Designation underscores need for therapies to treat severe hypoglycemia in the oncology setting REDWOOD C...
Rezolute to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on significantly improving outcomes for in...
Rezolute: RZ402 Could Be A Surprise Candidate In The Making
Topline results from phase 3 sunRIZE study, using ersodetug for the treatment of patients with congenital hyperinsulinism, expected in December 2025. Proof-of-concept was established in a phase 2 stud...
Rezolute, Inc. Announces Closing of Underwritten Offering
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies...
Rezolute 'Thrilled' With Positive Review Of Genetic Disorder Trial, Expects Topline Results In December
Rezolute, Inc. RZLT on Wednesday announced the Independent Data Monitoring Committee's (DMC) recommendation to continue the Phase 3 sunRIZE study as planned in patients with congenital hyperinsulinism...
Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies...
Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”)
Independent Data Monitoring Committee (the “DMC”) recommends continuation of sunRIZE trial as planned with no need to increase sample size Enrollment on track and expected to be completed in May 2025;...
Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors
REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc . (Nasdaq: RZLT), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with ...
Rezolute: Late-Stage Study Targeting Hyperinsulinism
Rezolute is a microcap biopharma focused on developing therapies for hypoglycemia caused by hyperinsulinism, with promising late-stage trials for RZ358 and RZ402. RZ358 targets Congenital Hyperinsulin...
Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), receives Breakthrough Therapy Designation and Orphan Drug Designation
Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Open-label arm (infant participants < 1 year old) has been recently reviewed by a Data Monitoring Committee (DMC) and target drug concentrations were safely reached at tested doses
Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference
REDWOOD CITY, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative thera...
Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative thera...
Rezolute: Ersodetug Downstream Tech Could Ignite The Hyperinsulinism Market
Rezolute, Inc. expects to report top-line results from the phase 3 sunRIZE study using ersodetug + placebo to treat patients with Congenital Hyperinsulinism in the 2nd half of 2025. The global Congeni...
Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update
FDA lifts partial clinical holds on ersodetug for the treatment of congenital HI; Phase 3 sunRIZE study to proceed in the U.S.
FDA Gives Green Signal To Rezolute's Genetic Disorder Treatment
Monday, the FDA removed partial clinical holds on Rezolute, Inc.'s RZLT RZ358 (ersodetug), a potential treatment for hypoglycemia (low blood sugar) caused by congenital hyperinsulinism (HI).
US FDA lifts partial clinical hold on Rezolute's blood sugar treatment
Rezolute Inc said on Monday the U.S. Food and Drug Administration has removed the partial clinical hold on its late-stage study testing its experimental treatment for low blood sugar.
FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study
Commencing study startup activities in the U.S.; participant enrollment anticipated in early 2025 Commencing study startup activities in the U.S.; participant enrollment anticipated in early 2025
Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
Second rare disease program with RZ358 in Phase 3 development Follows successful treatment of multiple patients with tumor hyperinsulinism under the Company's Expanded Access Program REDWOOD CITY, Cal...
Rezolute Announces Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement
Additional $6.7M in funding resulting in approximately $67M in gross proceeds Additional $6.7M in funding resulting in approximately $67M in gross proceeds
Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies ...
Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies ...
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies ...
Rezolute to Participate in the Jefferies Global Healthcare Conference
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transforma...
Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)
Met primary study endpoints: good safety profile and reduction in central subfield thickness (CST) First oral therapy to demonstrate reduction in macular edema; supports potential for early disease in...